top of page

Brain Cancer in Dogs

image.png

The most common types of brain cancer in dogs are meningiomas and gliomas, which can affect different areas of the brain. Meningiomas arise from the protective membranes covering the brain, while gliomas develop from the brain’s glial cells.

 

Older dogs, typically five years and older, are at a higher risk of developing brain cancer, with both male and female dogs being equally susceptible.

 

Brain tumors are categorized as either primary or secondary.

​

Primary brain tumors originate within the brain itself or in the layers surrounding it, known as the meninges. These tumors are localized to the brain and do not spread from other parts of the body.

​

Secondary brain tumors develop when cancer spreads to the brain from another part of the body. This can occur through metastasis, where cancer cells travel through the bloodstream or lymphatic system, or by invasion, where tumors directly grow into adjacent tissues.

CLINICAL TRIALS

Combined Cryoablation Immunotherapy of Spontaneous Canine Brain Tumors: A Feasibility and Safety Study

image.png

Principal Investigator

Constantinos G.  Hadjipanayis, M.D., Ph.D.

Center for Image-Guided Neurosurgery

Department of Neurological Surgery

University of Pittsburgh

Contact Number

Edward MacKillop DVM, DACVIM (Neurology)

Phone: 412-366-3400

Email: info.pitt@bluepearlvet.com

This clinical trial is a joint effort between BluePearl Pet Hospital and the Department of Neurological Surgery at the University of Pittsburgh, supported by the Neuroscience Research Foundation and The Alba Tull Center for Neuro Imaging and Therapeutics. The study aims to assess the feasibility and safety of a novel combination treatment for spontaneous canine brain tumors.

​

The treatment involves a dual approach: cryoablation, a procedure that destroys tumor tissue by freezing it, and direct intratumoral immunotherapy using a multi-target drug. This innovative combination is designed to stimulate the dog’s immune system to recognize and eliminate cancer cells, potentially offering a more effective solution for brain tumors that are resistant to standard therapies such as surgery, radiation, and chemotherapy.

Clinical Trial Inclusion Criteria

  • Dogs of any sex, aged 12 months or older.

  • Minimum body weight of 5 kg (11 pounds).

  • Clinical signs consistent with spontaneous brain tumors.

  • MRI confirmation of a brain tumor.

  • Life expectancy greater than 6 months.

Clinical Trial Exclusion Criteria

  • Dogs that are pregnant, nursing, or intended for breeding during the study period.

  • Tumors involving both hemispheres of the brain or those deemed untreatable by the clinical team.

  • Enrollment in any other clinical treatment trial.

  • Active systemic infections within one week of enrollment.

  • Significant systemic organ dysfunction (e.g., liver, kidney, or cardiac disease).

  • Known history of allergic reactions to compounds used in the study or contraindications for MRI (such as allergy to contrast agents, presence of metal implants, or known adverse reactions to inhalation anesthesia).

  • Youtube
  • Facebook
  • Instagram

©2024 Canine Cancer Alliance
 501(c)(3) Non-Profit Foundation
EIN 82-3762441

bottom of page